The genetic condition cystic fibrosis had no treatments on the NHS before 2019 and a Daily Express campaign - now a miracle one-a-day pill could make it vanish.

Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio. GlobalData provides trusted ...

“We are thrilled by the positive CHMP opinion in support of expanding the Kaftrio in combination with ivacaftor indication to include all CF patients 2 years and older who make CFTR protein,” said ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX Stock Outperforms Industry Image Source: Zacks Investment Research The ...

Kaftrio is the first drug that works in patients with the F508del and MF mutations, who account for around 90% of the overall CF population, and in trials led to improved lung function as well as ...

The company’s 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification ...

It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston ...

Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product revenues rose in the double-digit range for 10 consecutive years. In 2024 ...